TITLE

Role of Pramipexole in the Management of Parkinson's Disease

AUTHOR(S)
Antonini, Angelo; Barone, Paolo; Ceravolo, Roberto; Fabbrini, Giovanni; Tinazzi, Michele; Abbruzzese, Giovanni
PUB. DATE
October 2010
SOURCE
CNS Drugs;2010, Vol. 24 Issue 10, p829
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease and for the treatment of moderate-to-severe primary restless legs syndrome. A new extended-release formulation of pramipexole has now also been launched in Europe and the US to improve ease of use, compliance and provide a more continuous therapeutic effect over 24 hours. Before initiating any treatment, the benefit-risk ratio to the individual patient must be considered. For pramipexole in the treatment of Parkinson's disease, this means taking into account the available evidence regarding its symptomatic efficacy, effect on delaying long-term levodopa-related motor complications, beneficial effect on non-motor symptoms such as depression, and its safety and tolerability profile. Studies have shown that pramipexole is effective as monotherapy in early Parkinson's disease and as adjunctive therapy in advanced disease. Trials further suggest that the benefits of pramipexole may extend beyond the relief of motor symptoms (akinesia, rigidity and tremor at rest) to the amelioration of depressive symptoms in Parkinson's disease. Pramipexole is generally well tolerated; however, compared with levodopa treatment, pramipexole is associated with a higher rate of some dopaminergic adverse effects.
ACCESSION #
55821995

 

Related Articles

  • Pramipexole: A Review of its Use in the Management of Early and Advanced Parkinson's Disease. Dooley, M.; Markham, A. // Drugs & Aging;1998, Vol. 12 Issue 6, p495 

    Pramipexole is an orally active non-ergoline dopamine agonist with selective activity at dopamine receptors belonging to the D2 receptor subfamily (D, D, D receptor subtypes) and with preferential affinity for the D receptor subtype. It is approved as monotherapy in early Parkinson's disease and...

  • Dopamine Agonists in the Treatment of Parkinsons Disease-Past, Present and Future. Sit, S.Y. // Current Pharmaceutical Design;Aug2000, Vol. 6 Issue 12, p1211 

    An attempt is made by the author to highlight the important events that laid the foundation of dopamine agonists as a treatment strategy for Parkinsons disease. This debilitating neurodegenerative disorder is long recognized as a result of progressive cell loss in the substantia nigra of the...

  • Pramipexole Extended Release. Chwieduk, Claudine M.; Curran, Monique P. // CNS Drugs;2010, Vol. 24 Issue 4, p327 

    Pramipexole extended release (ER) is a non-ergolinic dopamine receptor agonist available for use as a once-daily oral treatment for the signs and symptoms of early and advanced idiopathic Parkinson's disease. Once-daily pramipexole ER and three times-daily pramipexole immediate release (IR) have...

  • INTRODUCTION: THE IMPACT OF CONTINUOUS LEVODOPA INFUSION IN THE TREATMENT OF PARKINSON'S DISEASE. Wolters, Erik // CNS Spectrums: The International Journal of Neuropsychiatric Med;April2008 Supplement 7, Vol. 13 Issue 4, p3 

    The article introduces various reports published within the issue including an article on the importance of steady-state blood L-dopa levels to reduce motor complications and an article about treatment strategies for Parkinson's disease that employ continuous dopaminergic stimulation.

  • Use and Tolerability of Cabergoline in Young and Older People with Parkinson's Disease: A Multi-Center Observational Study. Forbes, Alison; Brechany, Una; Stegie, Frauke; Stutt, Andrea; Chaudhuri, K. Ray; Appiah-Kubi, Linda S.; Nisbet, Angus; Burn, David J. // Journal of Applied Research;Fall2003, Vol. 3 Issue 4, p356 

    In the older patient with Parkinson's disease, dopamine agonists are often underused because of a perceived notion of poor tolerability secondary to side effects. Cabergoline is an ergot dopamine agonist with the longest half-life of its class, and, therefore, effective given once daily. This...

  • bromocriptine.  // Royal Society of Medicine: Medicines;2002, p121 

    The article presents information on bromocriptine, an ergot alkaloid used to treat parkinsonism. It works by stimulating the dopamine receptors in the brain and so is different to the more commonly used treatment with levodopa, which is converted to dopamine in the body. It is therefore...

  • Behavioural Adverse Effects of Dopaminergic Treatments in Parkinson's Disease. Antonini, Angelo; Cilia, Roberto // Drug Safety;2009, Vol. 32 Issue 6, p475 

    Treatment of Parkinson's disease has traditionally focused on the management of motor disability while behavioural disturbances have received less attention. Recently, impulse control disorders and aberrant repetitive behaviours have surged to clinical relevance as they occur during dopamine...

  • Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Drui, G; Carnicella, S; Carcenac, C; Favier, M; Bertrand, A; Boulet, S; Savasta, M // Molecular Psychiatry;Mar2014, Vol. 19 Issue 3, p358 

    Parkinson's disease (PD) involves the degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc) that is thought to cause the classical motor symptoms of this disease. However, motivational and affective impairments are also often observed in PD patients. These are...

  • In vitro dopaminergic neuroprotective and in vivo antiparkinsonian-like effects of Δ3,2-hydroxybakuchiol isolated from Psoralea corylifolia (L.). Zhao, G.; Zheng, X.-W.; Qin, G.-W.; Gai, Y.; Jiang, Z.-H.; Guo, L.-H. // Cellular & Molecular Life Sciences;May2009, Vol. 66 Issue 9, p1617 

    Cocktail recipes containing Psoralea corylifolia seeds (PCS) are used to empirically treat Parkinson disease. A PCS isolate Δ3,2-hydroxybakuchiol (BU) can inhibit dopamine uptake in dopamine transporter (DAT) transfected Chinese hamster ovary (CHO) cells, and dopamine reuptake blockade may...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics